Search | Clinical Trials Finder

Conditions: Colorectal Cancer
Interventions: 5 FU, Leucovorin, Oxaliplatin, capecitabine [Xeloda]; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 627 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2006
U.S. locations: 8
States / cities: Bakersfield, California • Colorado Springs, Colorado • Washington D.C., District of Columbia + 5 more

Conditions: Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer
Interventions: R-DXd, Bevacizumab, Carboplatin, Paclitaxel, Gemcitabine, Pegylated liposomal doxorubicin (PLD); Biological · Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 646 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 2
States / cities: Fountain Valley, California • Orlando, Florida

Conditions: Non Small Cell Lung Cancer
Interventions: Pegilodecakin, Pembrolizumab; Biological · Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 101 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 74
States / cities: Huntsville, Alabama • Tempe, Arizona • Beverly Hills, California + 66 more

Conditions: Small Cell Lung Carcinoma Extensive Disease
Interventions: Durvalumab, Tremelimumab, Carboplatin, Cisplatin, Etoposide; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 987 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2026
U.S. locations: 19
States / cities: Birmingham, Alabama • Scottsdale, Arizona • Rogers, Arkansas + 16 more

Conditions: Leukemia
Interventions: alemtuzumab, rituximab, fludarabine phosphate; Biological · Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2009
U.S. locations: 5
States / cities: Boston, Massachusetts • Jackson, Mississippi • New Brunswick, New Jersey + 1 more

Conditions: Metastatic Colorectal Cancer
Interventions: sorafenib, bevacizumab, mFOLFOX6 regimen; Drug
Lead sponsor: Accelerated Community Oncology Research Network; Other
Eligibility: 18 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 3
States / cities: Macon, Georgia • Billings, Montana • Memphis, Tennessee

Conditions: Non-small Cell Lung Cancer
Interventions: Sotorasib; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years and older
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 30
States / cities: Birmingham, Alabama • Tucson, Arizona • Duarte, California + 20 more

Conditions: Colorectal Carcinoma, Liver Metastases
Interventions: SIR-Spheres microspheres, FOLFOX6 cycles 1-3, FOLFOX6 cycles 4 onwards, Bevacizumab cycles 3 onwards; Device · Drug
Lead sponsor: Sirtex Medical; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 3
States / cities: Royal Oak, Michigan • Charlotte, North Carolina • Spokane, Washington

Conditions: Non-Small Cell Lung Cancer, Carcinoma, Non-Small-Cell Lung, Carcinoma, Non-Small-Cell Lung (NSCLC)
Interventions: Sigvotatug Vedotin, Pembrolizumab; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 714 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 84
States / cities: Fullerton, California • Golden, Colorado • Grand Junction, Colorado + 56 more

Conditions: NSCLC, Melanoma
Interventions: BA3071, Nivolumab, Pembrolizumab, Pemetrexed (Alimta); Biological · Drug
Lead sponsor: BioAtla, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 320 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 9
States / cities: Los Angeles, California • Atlanta, Georgia • Dyer, Indiana + 5 more

Conditions: Carcinoma of Unknown Primary
Interventions: capecitabine, docetaxel, gemcitabine hydrochloride, positron emission tomography; Drug · Procedure
Lead sponsor: University of Medicine and Dentistry of New Jersey; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2005
U.S. locations: 6
States / cities: Hamilton, New Jersey • Montclair, New Jersey • Morristown, New Jersey + 3 more

Conditions: Colorectal Cancer, Neoplasms, Colorectal
Interventions: CS7017, irinotecan, leucovorin, and 5-fluorouracil (5-FU) (FOLFIRI); Drug
Lead sponsor: Daiichi Sankyo; Industry
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 6
States / cities: Beverly Hills, California • Fullerton, California • Washington D.C., District of Columbia + 3 more

Conditions: Non-Small-Cell Lung, ALK-positive Advanced NSCLC, ALK-positive Non-small-cell Lung Cancer, ALK-positive NSCLC
Interventions: lorlatinib; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: New York, New York

Conditions: Metastatic Castration-resistant Prostate Cancer (mCRPC)
Interventions: Radium-223 (Xofigo, BAY88-8223), Abiraterone, Enzalutamide; Drug
Lead sponsor: Bayer; Industry
Eligibility: Male only
Enrollment: 346 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Whippany, New Jersey

Conditions: Carcinoma, Non-Small-Cell Lung
Interventions: Cisplatin, Gemcitabine, PF-3512676, Gemcitabine + Cisplatin; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 839 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 10
States / cities: Birmingham, Alabama • Bakersfield, California • Saint Joseph, Michigan + 4 more

Conditions: Head and Neck Cancer
Interventions: Nivolumab, BMS-986205, Cetuximab, Cisplatin, Carboplatin, Fluorouracil; Biological · Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Leiomyosarcoma
Interventions: Doxorubicin, L19TNF plus doxorubicin; Drug · Combination Product
Lead sponsor: Philogen S.p.A.; Industry
Eligibility: 16 Years to 100 Years
Enrollment: 114 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2025
U.S. locations: 8
States / cities: Phoenix, Arizona • Santa Monica, California • Jacksonville, Florida + 5 more

Conditions: Small Cell Lung Cancer (SCLC)
Interventions: Nab-paclitaxel, Gemcitabine; Drug
Lead sponsor: Muhammad Furqan; Other
Eligibility: 18 Years to 99 Years
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2022
U.S. locations: 1
States / cities: Iowa City, Iowa

Conditions: Head and Neck Squamous Cell Carcinoma, Head and Neck Cancer
Interventions: Tislelizumab, BGB-A425, LBL-007; Drug
Lead sponsor: BeiGene; Industry
Eligibility: 18 Years and older
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 9
States / cities: Los Angeles, California • Stanford, California • Lone Tree, Colorado + 6 more

Conditions: Advanced Bladder Urothelial Carcinoma, Advanced Renal Pelvis Urothelial Carcinoma, Advanced Ureter Urothelial Carcinoma, Advanced Urethral Urothelial Carcinoma, Metastatic Bladder Urothelial Carcinoma, Metastatic Renal Pelvis Urothelial Carcinoma, Metastatic Ureter Urothelial Carcinoma, Metastatic Urethral Urothelial Carcinoma, Stage III Bladder Cancer AJCC v8, Stage III Renal Pelvis and Ureter Cancer AJCC v8, Stage III Renal Pelvis Cancer AJCC v8, Stage III Ureter Cancer AJCC v8, Stage III Urethral Cancer AJCC v8, Stage IV Bladder Cancer AJCC v8, Stage IV Renal Pelvis and Ureter Cancer AJCC v8, Stage IV Renal Pelvis Cancer AJCC v8, Stage IV Ureter Cancer AJCC v8, Stage IV Urethral Cancer AJCC v8
Interventions: Avelumab, Biospecimen Collection, Bone Scan, Cabozantinib S-malate, Computed Tomography, Magnetic Resonance Imaging, Quality-of-Life Assessment, Questionnaire Administration; Drug · Procedure · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 654 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2029
U.S. locations: 271
States / cities: Phoenix, Arizona • Auburn, California • Berkeley, California + 214 more

Conditions: Urothelial Carcinoma, Bladder Cancer, Transitional Cell Carcinoma
Interventions: nab-paclitaxel, Gemcitabine; Drug
Lead sponsor: SCRI Development Innovations, LLC; Other
Eligibility: 18 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 5
States / cities: Fort Myers, Florida • St. Petersburg, Florida • West Palm Beach, Florida + 2 more

Conditions: Malignant Melanoma
Interventions: UV1, GM-CSF; Drug
Lead sponsor: Ultimovacs ASA; Industry
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2024
U.S. locations: 4
States / cities: Santa Monica, California • Iowa City, Iowa • Easton, Pennsylvania + 1 more

Conditions: Colorectal Cancer
Interventions: Cediranib, Bevacizumab, 5-fluorouracil ( in FOLFOX), Leucovorin (in FOLFOX), Oxaliplatin (in FOLFOX); Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 1,814 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2015
U.S. locations: 44
States / cities: Anniston, Alabama • Birmingham, Alabama • Casa Grande, Arizona + 41 more

Conditions: Colorectal Cancer
Interventions: Ramucirumab, Placebo, Irinotecan, Folinic Acid, 5-Fluorouracil; Biological · Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 1,072 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2016
U.S. locations: 92
States / cities: Sedona, Arizona • Tucson, Arizona • Fayetteville, Arkansas + 89 more

Search by objective public record fields.

A Study of Xeloda (Capecitabine) in Patients With Metastatic Colorectal Cancer

A Clinical Trial of Raludotatug Deruxtecan (R-DXd) With or Without Bevacizumab in Participants With Ovarian Cancer Who Have Progressed During Treatment With PARP-inhibitors Treatment on First Line Maintenance (MK-5909-008/ENGOT-ov107/GOG-3142 / REJOICE-Ovarian05)

Study of Pegilodecakin (LY3500518) With Pembrolizumab Compared to Pembrolizumab Alone First-line Tx in Participants With Metastatic Non-Small Cell Lung Cancer

Durvalumab ± Tremelimumab in Combination With Platinum Based Chemotherapy in Untreated Extensive-Stage Small Cell Lung Cancer (CASPIAN)

Fludarabine Combined With Either Alemtuzumab or Rituximab in Treating Patients With Refractory or Relapsed B-Cell Chronic Lymphocytic Leukemia

A Phase I Trial Evaluating mFOLFOX6 and Avastin With Nexavar as First-Line Treatment for Metastatic Colorectal Cancer

A Study of Sotorasib (AMG 510) in Participants With Stage IV NSCLC Whose Tumors Harbor a KRAS p.G12C Mutation in Need of First-line Treatment

FOLFOX6 Plus Sir-Spheres Microspheres Plus Avastin in Patients With Nonresectable Liver Metastases From Colorectal Carcinoma

This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.

A Phase 1/2 Study of BA3071 in Patients With Solid Tumors

Gemcitabine, Docetaxel, and Capecitabine in Treating Patients With Cancer of Unknown Primary Origin

Study of CS-7017 in Combination With FOLFIRI in Subjects With Metastatic Colorectal Cancer Who Failed First-Line Therapy

A Study to Learn About Patients With Non-Small Cell Lung Cancer (NSCLC) Who Took Lorlatinib as Their First Treatment

Descriptive Analysis of Clinical Outcomes in Patients With Prostate Gland Cancer, Which Spreads to Other Parts of the Body, Who Were Treated First With Novel Anti-hormone Therapy Followed by a Second Line Treatment With Novel Anti-Hormone Therapy or RadIum-223 (Xofigo).

Randomized Trial of Gemcitabine/Cisplatin + PF-3512676 vs Gemcitabine/Cisplatin Alone in Patients With Advanced NSCLC

An Immuno-therapy Study of Nivolumab in Combination With Experimental Medication BMS-986205 Compared to Standard of Care EXTREME Regimen in First-line Recurrent/Metastatic Squamous Cell Carcinoma of Head and Neck

Treatment of Metastatic Soft Tissue Sarcoma (STS) Patients (FIBROSARC USA)

Nab-Paclitaxel With Gemcitabine for Relapsed Small Cell Cancer

A Study of Tislelizumab in Combination With Investigational Agents in Participants With Head and Neck Squamous Cell Carcinoma

Testing the Addition of the Anti-cancer Drug, Cabozantinib, to the Usual Immunotherapy Treatment, Avelumab, in Patients With Metastatic Urothelial Cancer, MAIN-CAV Study

Nab-paclitaxel Plus Gemcitabine as First-line Therapy for Cisplatin-ineligible or Cisplatin-incurable Advanced Urothelial Carcinoma

UV1 Vaccine With Pembrolizumab for Patients With Unresectable or Metastatic Melanoma

First Line Metastatic Colorectal Cancer Therapy in Combination With FOLFOX

A Study in Second Line Metastatic Colorectal Cancer